Harrow Inc (NASDAQ:HROW), a specialty pharmaceutical company focused on ophthalmology, reported its fourth quarter and full-year 2025 financial results, delivering record revenue but falling short of Wall Street's profit expectations. The market's immediate reaction was sharply negative, with shares plummeting approximately 13% in after-hours trading.
Earnings Results Versus Estimates
The company's performance for the final quarter of 2025 presented a mixed picture. While top-line growth was robust, bottom-line profitability did not meet analyst forecasts.
- Revenue: Harrow reported Q4 2025 revenue of $89.1 million, a significant 33% increase year-over-year. This narrowly missed the analyst consensus estimate of approximately $90.2 million.
- Earnings Per Share (EPS): The company posted non-GAAP EPS of $0.26 for the quarter. This fell meaningfully short of the $0.38 per share that analysts had projected.
The revenue miss, though slight, combined with the more substantial EPS shortfall, appears to be the primary driver behind the negative investor sentiment in the extended session. The market is signaling disappointment that strong sales growth did not translate more efficiently to the bottom line.
Market Reaction and Recent Performance
The after-hours drop of nearly 13% represents a stark reversal from the stock's recent positive trajectory. Prior to the earnings release, HROW shares had been on an upward trend, gaining roughly 31% over the past month. This suggests investors entered the report with elevated expectations, which were not met by the actual EPS figure. The sharp sell-off indicates a repricing based on the earnings disappointment, effectively erasing a portion of those recent gains.
Key Highlights from the Report
Beyond the headline numbers, Harrow's press release emphasized several operational and financial milestones for the period:
- The $89.1 million in Q4 revenue set a new company record.
- The full-year 2025 results and initial financial guidance for 2026 were also announced alongside the quarterly figures, indicating management is providing a forward-looking roadmap to investors.
Looking Ahead: 2026 Guidance Versus Estimates
The company provided its financial outlook for the full year 2026, which offers a point of comparison against existing analyst models.
- Analyst Estimates for 2026: Currently, analysts are forecasting full-year 2026 sales of approximately $394 million and an EPS of $1.42.
- Harrow's 2026 Guidance: While the press release confirms guidance was issued, the specific numerical targets were not detailed in the provided summary. A comparison to analyst estimates is therefore not possible from the available information. Investors will need to review the full release to assess whether management's projections are above, in line with, or below current Street expectations for the coming year.
For the immediate next quarter, analyst consensus estimates project Q1 2026 sales of about $69.9 million and an EPS loss of $0.06.
For a detailed breakdown of historical earnings, future estimates, and analyst projections, you can review more data on Harrow's earnings and estimates page.
Disclaimer: This article is for informational purposes only and does not constitute financial advice, investment recommendation, or an offer to buy or sell any securities. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions.
